Asfotase alfa

From WikiMD.org
Jump to navigation Jump to search

Asfotase Alfa (pronounced as-FO-tase AL-fa) is a medication used to treat a rare genetic disorder known as Hypophosphatasia (HPP).

Etymology

The name "Asfotase Alfa" is derived from the enzyme it replaces, "alkaline phosphatase," and "alfa," a common suffix in pharmaceutical naming indicating the first in a series or class.

Usage

Asfotase Alfa is used to treat patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP). HPP is a rare, genetic, metabolic disease where there is a deficiency of the tissue-nonspecific alkaline phosphatase (TNSALP) enzyme, leading to a variety of systemic complications. Asfotase Alfa is a recombinant human TNSALP enzyme replacement therapy that aims to restore the enzyme activity in patients with HPP.

Dosage

The dosage of Asfotase Alfa varies depending on the patient's weight and the severity of the condition. It is administered via subcutaneous injection.

Side Effects

Common side effects of Asfotase Alfa include injection site reactions, lipodystrophy (abnormal fat distribution), ectopic calcifications, and allergic reactions.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski